ChiCTR2600126507 版本V1.0 版本创建时间2026/06/10 10:56:15 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600126507 

最近更新日期:

Date of Last Refreshed on:

2026-06-10 10:56:07 

注册时间:

Date of Registration:

2026-06-10 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于亚体素QSM多成分定量成像及纹理分析技术在帕金森病诊断及分期的应用研究

Public title:

Application Research of Sub-voxel QSM Multi-component Quantitative Imaging and Texture Analysis Technology in Diagnosing and Staging Parkinson's Disease

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于亚体素QSM多成分定量成像及纹理分析技术在帕金森病诊断及分期的应用研究

Scientific title:

Application Research of Sub-voxel QSM Multi-component Quantitative Imaging and Texture Analysis Technology in Diagnosing and Staging Parkinson's Disease

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

林圣美 

研究负责人:

林圣美 

Applicant:

Lin Shengmei 

Study leader:

Lin Shengmei 

申请注册联系人电话:

Applicant telephone:

+86 13705032943

研究负责人电话:

Study leader's
telephone:

+86 591 8821 6266

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

295237790@qq.com

研究负责人电子邮件:

Study leader's E-mail:

295237790@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

福建省福州市鼓楼区东街134号

研究负责人通讯地址:

福建省福州市鼓楼区东街134号

Applicant address:

No. 134 Dongjie Street, Gulou District, Fuzhou City, Fujian Province

Study leader's address:

No. 134, East Street, Fuzhou City, Fujian province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

福州大学附属省立医院

Applicant's institution:

Fuzhou university Affiliated Provincial Hospital

研究负责人所在单位:

福州大学附属省立医院

Affiliation of the Leader:

Fuzhou University Affiliated Provincial Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

伦审科研第(K2026-05-017)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

福州大学附属省立医院伦理委员会

Name of the ethic committee:

Ethics Committee of Fuzhou University Affiliated Provincial Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2026-05-11 00:00:00

伦理委员会联系人:

练发杨

Contact Name of the ethic committee:

Lian FaYang

伦理委员会联系地址:

福建省福州市鼓楼区东街134号

Contact Address of the ethic committee:

No. 134, East Street, Fuzhou City, Fujian province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 591 88216023

伦理委员会联系人邮箱:

Contact email of the ethic committee:

fjslec@163.com

研究实施负责(组长)单位:

福州大学附属省立医院

Primary sponsor:

Fuzhou University Affiliated Provincial Hospital

研究实施负责(组长)单位地址:

福建省福州市鼓楼区东街134号

Primary sponsor's address:

No. 134, East Street, Fuzhou City, Fujian province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

福建省

市(区县):

Country:

China

Province:

Fujian

City:

单位(医院):

福州大学附属省立医院

具体地址:

福建省福州市鼓楼区东街134号

Institution
hospital:

Fuzhou University Affiliated Provincial Hospital

Address:

No. 134, East Street, Fuzhou City, Fujian province

经费或物资来源:

福建省卫生健康中青年骨干培养项目

Source(s) of funding:

Fujian Provincial Health Commission Project for the Cultivation of Middle-aged and Young Talents

研究疾病:

帕金森病  

Target disease:

Parkinson's disease

研究疾病代码:

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

诊断试验诊断准确性 

Study design:

Diagnostic test for accuracy 

研究目的:

本研究拟采集临床可疑PD的患者一般临床资料及临床量表评估数据,收集磁共振多参数成像资料。应用磁共振磁化率定量成像技术QSM于帕金森病诊断、鉴别诊断及临床分期中,不需要额外进行扫描,依托多回波扰相梯度回波序列采集非高通滤波的相位信息及幅度信息,单次5分钟扫描就能同步获取解剖结构与功能代谢、铁沉积及髓鞘磷脂改变等多维度信息。研究目的:(1)借助深度学习技术,实现铁定量与髓鞘磷脂亚体素分离,提升空间解析度,评价帕金森病不同临床分期多成分定量成像的改变。(2)应用 QSM 图像进行亚体素铁定量分析及纹理分析,包括基底节区核团、中脑黑质纹状体系统、小脑齿状核区的磁化率值及纹理特征参数,建立稳健的多参数影像诊断模型,对 PD 患者早期诊断及鉴别诊断提供支持性证据。  

Objectives of Study:

This study aims to collect general clinical data and clinical scale assessment data of patients with suspected Parkinson's disease (PD), as well as magnetic resonance multi-parameter imaging data. The quantitative magnetic susceptibility mapping (QSM) technique of magnetic resonance imaging is applied in the diagnosis, differential diagnosis, and clinical staging of Parkinson's disease. No additional scanning is required. The non-high-pass filtered phase information and amplitude information are collected through multi-echo phase-encoding gradient echo sequences, and all the multi-dimensional information such as anatomical structure and functional metabolism, iron deposition, and myelin lipid changes can be simultaneously obtained within a single 5-minute scan. Research objectives: (1) Using deep learning technology to achieve iron quantification and separation of myelin phospholipid subvoxels, improve spatial resolution, and evaluate changes in multi-component quantitative imaging at different clinical stages of Parkinson's disease. (2) Apply QSM images for subvoxel iron quantification and texture analysis, including susceptibility values and texture feature parameters of basal ganglia nuclei, midbrain substantia nigra-striatum system, and cerebellar dentate nucleus region, to establish a robust multiparametric imaging diagnostic model and provide supportive evidence for early diagnosis and differential diagnosis of PD patients.Research objectives: (1) Using deep learning technology to achieve iron quantification and separation of myelin phospholipid subvoxels, improve spatial resolution, and evaluate changes in multi-component quantitative imaging at different clinical stages of Parkinson's disease. (2) Apply QSM images for subvoxel iron quantification and texture analysis, including susceptibility values and texture feature parameters of basal ganglia nuclei, midbrain substantia nigra-striatum system, and cerebellar dentate nucleus region, to establish a robust multiparametric imaging diagnostic model and provide supportive evidence for early diagnosis and differential diagnosis of PD patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.基于临床收集可疑帕金森病及帕金森综合征的患者,最终诊断符合中华医学会神经病学分会 2016 年制定的《中国帕金森病的诊断标准》纳入。 2.对照组: 纳入健康自愿者 30 例,无严重精神障碍病史,无神经系统变性史、外伤史、肿瘤病史。无磁共振检查禁忌症等。

Inclusion criteria

1. Patients suspected of Parkinson's disease and Parkinsonian syndromes were collected based on clinical data, and those whose final diagnosis met the "Diagnostic Criteria for Parkinson's Disease in China" formulated by the Neurology Branch of the Chinese Medical Association in 2016 were included. 2. Control group: 30 healthy volunteers were included, with no history of severe mental disorders, no history of neurodegenerative diseases, trauma, or tumors. No contraindications for MRI examination, etc.

排除标准:

1. 帕金森叠加综合征包括阿尔茨海默病、血管性痴呆、精神类疾病; 2. 没有完成临床量表的患者; 3. 磁共振检查依从性差或存在磁共振检查禁忌症,如存在心脏起搏器、人工电子耳蜗、眼球内金属异物、幽闭恐惧症、妊娠等情况; 4. MRI 图像质量差,如存在严重震颤、异动症、QSM 图像难以分析。

Exclusion criteria:

1. Parkinsonism overlap syndrome includes Alzheimer's disease, vascular dementia, and psychiatric disorders; 2. Patients who have not completed clinical scales; 3. Poor compliance with MRI examination or contraindications to MRI, such as having a cardiac pacemaker, artificial cochlea, metallic foreign body in the eye, claustrophobia, pregnancy, etc.; 4. Poor MRI image quality, such as severe tremor, dyskinesia, or difficulty analyzing QSM images.

研究实施时间:

Study execute time:

From 2026-01-01 00:00:00 To 2028-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-07-01 00:00:00 To 2027-12-31 00:00:00

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

最终诊断应该符合2016年制定的《中国帕金森病的诊断标准》。确定帕金森综合征的诊断是帕金森病诊断的先决条件。帕金森综合征的诊断基于3个核心运动症状,即必备“运动迟缓”,以及“静止性震颤”或“肌强直”2项症状或体征中的1项。支持标准有4条:(1)患者对多巴胺能药物的治疗有显著疗效;(2)出现左旋多巴诱导的异动症;(3)临床体检观察到单个肢体的静止性震颤;(4)辅助检查:“嗅觉减退或丧失”或“头颅超声显示黑质异常高回声(>20 mm2)”或心脏间碘苄胍闪烁显像法显示心脏去交感神经支配。

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

The final diagnosis should comply with the "Diagnostic Criteria for Parkinson's Disease in China" established in 2016. Determining the diagnosis of parkinsonian syndrome is a prerequisite for diagnosing Parkinson's disease. The diagnosis of parkinsonian syndrome is based on three core motor symptoms: the mandatory 'bradykinesia,' and one of the other two symptoms or signs, 'resting tremor' or 'muscle rigidity.' There are four supportive criteria: (1) the patient shows significant therapeutic effects from dopaminergic drugs; (2) levodopa-induced dyskinesia occurs; (3) resting tremor is observed in a single limb during clinical examination; (4) auxiliary examinations: 'olfactory reduction or loss,' or 'cranial ultrasound shows abnormally high echogenicity in the substantia nigra (>20 mm2),' or cardiac iodine-123-metaiodobenzylguanidine scintigraphy shows cardiac sympathetic denervation.

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

多参数影像诊断模型 ,包阔诊断的灵敏度、特异度、阳性预测值、阴性预测值、诊断准确性。

Index test:

Multiparametric Imaging Diagnostic Model , covering the sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy of the diagnosis.

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

回顾性病例 100 例,前瞻性病例 300 例,健康自愿者 30 例

例数:

Sample size:

430

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

Retrospective cases: 100, prospective cases: 300, healthy volunteers: 30

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

需要排除多系统萎缩、进行性核上性眼肌麻痹、额颞叶痴呆、皮质基底节变性。或者明确记录到可导致帕金森综合征或疑似与患者症状相关的其他疾病,或基于整体诊断学评估,专业医生认为或为其他综合征,而非帕金森病。

例数:

Sample size:

0

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

It is necessary to rule out multiple system atrophy, progressive supranuclear palsy, frontotemporal dementia, and cortical-basal ganglia degeneration. Any other diseases that could lead to Parkinson's syndrome are suspected to be related to the patient's symptoms should be ruled out.

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

福建省 

市(区县):

 

Country:

China

Province:

Fujian

City:

单位(医院):

福州大学附属省立医院 

单位级别:

三级甲等 

Institution
hospital:

Fuzhou University Affiliated Provincial Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

诊断准确性

指标类型:

主要指标

Outcome:

Diagnostic accuracy

Type:

Primary indicator

测量时间点:

病例全部收集完成至多参数诊断模型建立完成

测量方法:

Measure time point of outcome:

All cases will be collected before the establishment of the multi-parameter diagnostic model

Measure method:

指标中文名:

灵敏度

指标类型:

次要指标

Outcome:

Sensitivity

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

特异度

指标类型:

次要指标

Outcome:

specificity

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

阳性预测值

指标类型:

次要指标

Outcome:

positive predictive value

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

阴性预测值

指标类型:

次要指标

Outcome:

negative predictive value

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集采用病例记录表,数据管理采用电子管理系统,由双人进行保管。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection is conducted using case record forms(CRF), and data management is carried out through an electronic management system, which is kept by two individuals.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2026-06-10 10:56:07